DOXORUBICIN 2MG-MLVIAL 2 mg/ml Concentrate for solution for infusion 5ml Vial

Product Overview

Doxorubicin 2 mg/ml Concentrate for solution for infusion is an essential medication utilized in comprehensive cancer therapy.
As a potent anthracycline cytotoxic agent, it plays a critical role in various chemotherapy regimens by interfering with the genetic material of cancer cells, thereby inhibiting their growth and division.
This sterile solution is specifically formulated for intravenous administration and is typically employed under the strict supervision of healthcare professionals experienced in the use of chemotherapeutic agents.
It is supplied in a 5ml vial, containing a concentrated form that requires dilution prior to infusion.

Benefits of Use

• Effective in treating a wide array of solid tumors and hematological malignancies.
• Often incorporated into combination chemotherapy protocols for enhanced therapeutic outcomes.
• Contributes significantly to the management of various cancers, including breast cancer, lymphomas, leukemias, soft tissue and osteogenic sarcomas, ovarian cancer, bladder cancer, and thyroid cancer.

How to Use

1. Doxorubicin is administered exclusively by slow intravenous infusion.
2. The concentrate must be diluted with an appropriate sterile solution (e.g., sodium chloride 0.9% or glucose 5%) before administration.
3. Administration should only be performed by personnel trained in the handling and administration of cytotoxic agents, under the direct supervision of a qualified physician.
4. Dosage and administration schedule are highly individualized and determined by the patient's specific cancer type, stage, previous treatments, and overall health status.
5. Great care must be taken to avoid extravasation (leakage outside the vein) as it can cause severe local tissue damage.

Caution & Warnings

• Cardiotoxicity: Doxorubicin carries a significant risk of severe, potentially irreversible cardiotoxicity (heart damage). Regular monitoring of cardiac function (e.g., ECG, echocardiogram) is crucial before, during, and after treatment.
• Myelosuppression: Significant bone marrow suppression (decreased white blood cells, red blood cells, and platelets) is a common dose-limiting toxicity. Complete blood counts must be monitored frequently throughout therapy.
• Secondary Malignancies: There is an increased risk of developing secondary leukemias or myelodysplastic syndrome following doxorubicin treatment.
• Extravasation: If leakage from the vein occurs, it can lead to severe local tissue necrosis. Immediate and appropriate measures must be taken if extravasation is suspected.
• Liver and Kidney Impairment: Dose adjustments may be necessary in patients with impaired liver or kidney function.
• Pregnancy and Lactation: Doxorubicin is teratogenic and can cause fetal harm. Effective contraception is required for patients of reproductive potential during and for a period after treatment. It is contraindicated during breastfeeding.
• Immunosuppression: Due to its immunosuppressive effects, the administration of live vaccines should be avoided during doxorubicin therapy.

Ingredients

• Active Ingredient: Doxorubicin Hydrochloride (2 mg/ml)
• Inactive Ingredients: Water for Injection, Sodium Chloride

Product Details

Doxorubicin is a potent antineoplastic agent belonging to the anthracycline class.
It exerts its cytotoxic effects primarily through intercalation into DNA, inhibition of topoisomerase II, and the generation of reactive oxygen species.
These mechanisms lead to DNA damage, inhibition of DNA and RNA synthesis, and ultimately, programmed cell death in rapidly proliferating cancer cells.
This 5ml vial contains 2 mg/ml of Doxorubicin concentrate, ensuring precise dosing for infusion preparations.
It remains a critical component in various multimodal cancer treatment plans, often used in combination with other chemotherapeutic agents or radiation therapy to achieve optimal patient outcomes.